The promise of CAR-T therapy is immense, but its delivery remains perilous. For every patient who achieves a durable remission, another may face severe, sometimes fatal, immune reactions. A Seattle startup, Q-Immune, is betting that the answer to this uncertainty lies not in the clinic, but in the complex protein networks inside a living cell, measured at scale and decoded by machine learning.
Founded in 2025, Q-Immune is building a two-pronged service for biopharmaceutical R&D teams. Its core offering combines a wet-lab testing service with a SaaS analytics platform, all centered on a technique called quantitative multiplex immunoprecipitation (QMI). The goal is to generate a functional blueprint of a cell therapy construct by measuring the physical interactions of hundreds of native proteins simultaneously. This high-dimensional data is then fed into AI models designed to predict clinical safety and efficacy long before a therapy reaches a Phase I trial [Life Science Washington Institute, April 2025].
The bet on a predictive blueprint
Q-Immune's fundamental assertion is that traditional, single-endpoint assays are insufficient for forecasting how a complex living therapy will behave in a complex living patient. By mapping the dynamic signaling pathways within engineered immune cells, the company aims to uncover biosignatures that correlate with outcomes like cytokine release syndrome or neurotoxicity. The commercial wedge is a practical one: a pre-clinical validation service. For a biotech sponsor, the value proposition is de-risking the multi-million dollar leap into human trials.
| Role | Name | Background Note |
|---|---|---|
| Chief Executive Officer | Cameron McCann | Seattle-based entrepreneur listed as co-founder and CEO [RocketReach, 2026]. |
| Chief Scientific Officer | Stephen Smith, Ph.D. | Researcher with published work on QMI and array tomography; previously co-founded the social app WhosHere [Brain & Behavior Research Foundation] [TechCrunch, 2012]. |
Stephen Smith's academic research provides a direct technical foundation. His work employed QMI to measure protein interactions linked to neurological conditions, a methodological through-line to Q-Immune's approach for immunology [Brain & Behavior Research Foundation].
The crowded field of de-risking biotech
Q-Immune is not operating in a vacuum. The broader market for tools that accelerate and de-risk therapeutic R&D is crowded and well-funded. Its specific approach, however, carves out a niche. Unlike companies focused solely on in silico molecule design or AI-driven novel target discovery, Q-Immune's differentiation hinges on generating proprietary, high-fidelity wet-lab data from actual cell therapy constructs. This grounds its AI predictions in empirical biology, a potentially crucial advantage for regulatory credibility.
The company's early-stage status presents both its greatest opportunity and its most evident challenges. Being pre-seed and without publicly announced funding or pharma partnerships means it is still in the phase of proving its core technology. The risks are substantial:
- Clinical validation. The ultimate test is a prospective, blinded study showing its predictions accurately forecast trial results.
- Commercial adoption. Convincing large, risk-averse pharmaceutical companies to adopt a new, unproven pre-clinical standard requires navigating lengthy enterprise sales cycles.
- Technical scalability. Running multiplex proteomics at the throughput and consistency required for industrial R&D is a non-trivial engineering and operational hurdle.
What standard care looks like today
For patients with relapsed or refractory blood cancers, the current standard of care for CAR-T therapy is a harrowing journey. After their T-cells are extracted and genetically re-engineered, they undergo a conditioning chemotherapy regimen to wipe out their existing immune system before the modified cells are reinfused. Physicians then monitor closely for signs of cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome. Q-Immune's ambition is to shift this paradigm, moving prediction upstream into the lab where the therapy is designed, aiming to deliver safer, more effective treatments to this vulnerable population from the very first dose.